linjc16/ctgov huggingface dataset:
Interplay Between Oxytocin and Cortisol During Stress in Borderline Personality Disorder

Study Overview
=================
Brief Summary
-----------------
This study aims to determine the feasibility and preliminary data on the interaction between oxytocin and cortisol during stress in borderline personnality disorder.

Detailed Description
-----------------
The investigators will recruit 10 female patients with borderline personnality disorder and 10 controls with no psychiatric diagnosis, aged between 18 and 25 years old. salivary cortisol daily curve ( 6 measures during the day) will be measured in participant's naturalistic environnement, together with salivary oxytocin. In addition, salivary oxytocin and cortisol will be measured during a psychosocial stress task and recovery.

Official Title
-----------------
Feasibility and Preliminary Data on the Interplay Between Oxytocin and Cortisol During Stress in Borderline Personality Disorder

Conditions
-----------------
Borderline Personality Disorder, Oxytocin

Intervention / Treatment
-----------------
* Other: stress test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Borderline personality disorder-DSM V Exclusion Criteria: Schizophrenia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Borderline personality disorder<br>female patients between 18 and 25 years old meeting DSM V criteria for borderline personality disorder | Other: stress test<br>* TSST- psychosocial stress test<br>|
| Control<br>female participants between 18 and 25 years old, with no psychiatric history, not meeting criteria for borderline personality disorder | Other: stress test<br>* TSST- psychosocial stress test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Salivary cortisol | salivary cortisol measured with salivettes (swabs) | Baseline | 
| Salivary cortisol | salivary cortisol measured with salivettes (swabs) | Change in one day (circadian cortisol with 6 measures within one day | 
| Salivary cortisol | salivary cortisol measured with salivettes (swabs) | Change during experimental task (up to 2 hours) | 
| Salivary oxytocin | salivary oxytocin measured with salivettes (swabs) | Baseline | 
| Salivary oxytocin | salivary oxytocin measured with salivettes (swabs) | Two measures within one day | 
| Salivary oxytocin | salivary oxytocin measured with salivettes (swabs) | Change during experimental task (up to 2 hours) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cortisol, tsst, borderline personnality, stress
Neuropsychological Testing Using Mobile Devices

Study Overview
=================
Brief Summary
-----------------
The purpose of this studying is to develop and characterize neuropsychological testing software for evaluating the prefrontal and temporal function of patients. As no software has been used for this purpose, this study will gather pilot data on the baseline performance of patients in a hospital setting that lack any neurological impairment. After creating this baseline, later experiments can be proposed to compare the performance in normal subjects with those who have neurologic injury or disease.

Official Title
-----------------
Neuropsychological Testing Using Mobile Devices

Conditions
-----------------
Inpatients With Normal Neurological Function

Intervention / Treatment
-----------------
* Behavioral: Neurological testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Inpatients > = 18 years of age Patient must be able to provide informed consent Exclusion Criteria: Patients with score of < 26 on Folstein Mini-Mental Status Exam Patients with known brain lesions Patients with history of stroke, neurologic disease or dementia Patients with acute illness or who are in imminent distress

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Normal patients<br>for patients with normal score on neurological testing with Folstein Mini-Mental Status Exam will then take the Scenes Task | Behavioral: Neurological testing<br> <br> * Other names: Folstein Mini-Mental Status Exam;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of normal performance curve | The purpose of this study is to generate a curve of normal performance on the neurological test for hospitalized patients of different ages | 1 year |
Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly

Study Overview
=================
Brief Summary
-----------------
The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).

Official Title
-----------------
An Open, Randomised, Multicentre Study to Compare Buprenorphine Transdermal Delivery System (BTDS) With Standard Treatment in Elderly Subjects With OA of the Hip and/or Knee

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Drug: Buprenorphine
* Drug: Codeine paracetamol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Either sex aged 65 or above Diagnosis of OA of the hip and/or knee Severe pain requiring step two medication Taking maximum dose of paracetamol Exclusion Criteria: Painful disease of the joints other than OA Contraindication to buprenorphine, other opioids, patch adhesives or nonsteroidal anti-inflammatory agents (NSAIDS) Subjects taking cyclooxygenase (COX) II selective inhibitors

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: buprenorphine transdermal system<br>Buprenorphine transdermal 7 day analgesic patch | Drug: Buprenorphine<br>* buprenorphine transdermal system 5, 10 and 20 mg<br>* Other names: BuTrans/Norspan;|
| Active Comparator: codeine paracetamol tablets<br>codeine paracetamol combination tablets | Drug: Codeine paracetamol<br>* combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500<br>* Other names: Co-codamol tablets;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average Daily Pain Scores - BS11 Pain Scores. | The primary efficacy variable was the average daily pain score recorded on a Box Scale-11 pain scale in the evening. 0 = no pain and 10 = most pain imaginable. Subjects ticked the box from 0 - 10 which best describes their level of pain. | every day over a 12 week study duration. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
OA, Elderly, Pain, OA of the hips and/or knees
Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to determine whether there are differences in bioelectrical function (measured by amplitude integrated electroencephalography) and brain oxygenation (measured by near infrared spectroscopy) while and after instillation of two different surfactant preparations.

Detailed Description
-----------------
Patients randomized to one of the treatment groups: 1) SRT with porcine preparation - poractant alfa; 2) SRT with bovine preparation - beractant. Continuous monitoring and simultaneous recordeding of 1) saturation (SpO2) and heart rate (HR) measured with pulse oximetry, cerebral tissue oxygenation measured with near-infrared spectroscopy, amplitude-integrated electroencephalography.

Official Title
-----------------
Assessment of the Cerebral Tissue Oxygenation and the Bioelectrical Brain Activity of Preterm Newborns During Administration of Two Different Surfactant

Conditions
-----------------
Respiratory Distress Syndrome, Newborn, Respiratory Failure

Intervention / Treatment
-----------------
* Drug: Poractant alfa instillation
* Drug: Beractant instillation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 26-30 gestational age surfactant instillation Exclusion Criteria: congenital heart disease congenital central nervous disorder congenital genetic disorders

Ages Eligible for Study
-----------------
Minimum Age: 15 Minutes
Maximum Age: 2 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Poractant goup<br>Newborns, who will be monitored by amplitude integrated electroencephalography (aEEG) and near infrared spectroscopy (NIRS) during poractant instillation. | Drug: Poractant alfa instillation<br>* aEEG and NIRS monitoring during poractant alfa instilation<br>|
| Active Comparator: Beractant group<br>Newborns who will be monitored by aEEG and NIRS during beractant instillation | Drug: Beractant instillation<br>* aEEG and NRs monitoring during beractant instillation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cerebral oxygenation | Cerebral tissue oxygenation measured with near-infrared spectroscopy | 4 hours after surfactant instillation | 
| Brain bioelectrical activity | Brain bioelectrical activity measured with amplitude-integrated electroencephalography (aEEG) | 4 hours after surfactant instillation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brain oxygenation, NIRS, aEEG, surfactant
Direct Measurement of Proinsulin Clearance in Humans

Study Overview
=================
Brief Summary
-----------------
Researchers are trying to determine how quickly proinsulin is cleared from the circulation.

Detailed Description
-----------------
proinsulin clearance is necessary to determine the rate of secretion into the circulation

Official Title
-----------------
Direct Measurement of Proinsulin Clearance in Humans

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: Somatostatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Weight-stable, non-diabetic subjects from Biobank participants at Mayo Clinic, Rochester Exclusion Criteria: Age < 25 or > 65 years (to avoid studying subjects who could have latent type 1 diabetes, or the effects of age extremes in subjects with normal or impaired fasting glucose). HbA1c ≥ 6.5% Use of glucose-lowering agents. For female subjects: positive pregnancy test at the time of enrollment or study History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy. Active systemic illness or malignancy. Symptomatic macrovascular or microvascular disease. Hormone replacement therapy >0.625 mg premarin daily

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: proinsulin clearance<br>all participants will be studied once where somatostatin will be used to block endogenous insulin secretion | Drug: Somatostatin<br>* infused to block endogenous insulin secretion over a 4 hour period<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proinsulin Clearance | The half-life of proinsulin in a given individual | through study completion, each study will take an average of 8 hours | 
| Proinsulin Distribution | The volume of distribution of proinsulin in a given individual | through study completion, each study will take an average of 8 hours |
the Antibacterial Effect of Zinc ,Silver and Fluoride

Study Overview
=================
Brief Summary
-----------------
natural teeth will be filled with the 3 different material then the dentin sample will be collected ,bacterial culture and elementary analysis will be done

Detailed Description
-----------------
orthodontic patient with premolar indicated for extraction , teeth will restored with the different material 3 months before doing extraction

Official Title
-----------------
the Antibacterial Effect of Different Glass Ionomer Restoration Containing Zinc ,Silver and Fluoride Ion:in Situ Study

Conditions
-----------------
Dental Caries

Intervention / Treatment
-----------------
* Procedure: silver modified glass ionomer
* Procedure: zinc modified
* Procedure: conventional glass ionomer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient need teeth extraction for orthodontic treatment Exclusion Criteria: carious teeth deciduous teeth

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: conventional glass ionomer<br> | Procedure: conventional glass ionomer<br>* occlusal cavity filled with conventional glass ionomer<br>|
| Experimental: zinc modified glass ionomer<br> | Procedure: zinc modified<br>* occlusal cavity filled with zinc modified<br>|
| Experimental: silver modified glass ionomer<br> | Procedure: silver modified glass ionomer<br>* occlusal cavity filled with silver modified<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bacterial count | streptococcus mutant count by culture of dentin sample excavated from the tooth after restoration removal | 3months | 
| elementary analysis of dentin | elementary analysis of dentin component excavated from the cavity after restoration removal to detect the change in tooth mineral | 3months |
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Study Overview
=================
Brief Summary
-----------------
To evaluate long-term safety and efficacy of pregabalin in patients with partial seizures.

Official Title
-----------------
Pregabalin Open-Label, Multicenter Add-On Trial Following a 4-Day Double-Blind Transition Period to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.

Conditions
-----------------
Seizure Disorder, Partial

Intervention / Treatment
-----------------
* Drug: Pregabalin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have met the inclusion criteria for preceding double-blind study Have received double-blind study medication and wish to receive open-label pregabalin. Exclusion Criteria: Cannot have absence seizures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pregabalin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety Efficacy |  |  |
Platelet Rich Plasma Injection Into Ovary of Patients With Premature Ovarian Insufficiency

Study Overview
=================
Brief Summary
-----------------
All encountered cases with POI will be assessed and examined then investigated. Eligible cases will be included in the study

Detailed Description
-----------------
Patients will be subjected to injection of autologous PRP inside the ovary about 0.5-1 mml by laparoscopy

Official Title
-----------------
Platelet Rich Plasma Injection Into Ovary of Patients With Premature Ovarian Insufficiency

Conditions
-----------------
Premature Ovarian Failure

Intervention / Treatment
-----------------
* Procedure: PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Premature ovarian insufficiency diagnosed by: FSH> 40 Amenorrhea Menopuasal symptoms Infertility Exclusion Criteria: Refusal to participate Secondary POI due chemotherapy, surgery, or radiotherapy Previous treatment with PRP

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: All eligible patient will recieve the treatment with PRP
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PRP injection<br>injection of PRP inside ovary by the assistance of laparoscopy | Procedure: PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml<br>* intraovarian injection of 2 mml of PRP by laparoscopic guide<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resumption of ovarian hormonal function | Measurement of Estradiol level on Day 3 of cycle | 3-6 months | 
| Resumption of ovarian folliclugenesis | Assessment of the presence of oocytes by trans vaginal ultrasound on day 3 | 3-6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Resumption of menstruation | Occurrence of Menstruation after secondary amenrorrhea by questionnaire | 3-6 months | 
| Fertility potential | Potential to get pregnant after ICSI procedure | 3-6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Premature ovarian insuffiency, Infertility, PRP
Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma

Study Overview
=================
Brief Summary
-----------------
This study aims to assess the technical performance of Tc-99m tetrofosmin SPECT as compared to F-18 FDG PET for the differentiation of radiation necrosis from glioma relapse and to obtain estimates of diagnostic accuracy for Tc-99m tetrofosmin SPECT and F-18 FDG PET in an intra-individual comparison.

Official Title
-----------------
Exploratory Phase II Study in Patients After Treatment of High Grade Brain Tumors to Assess the Technical Performance of Tc-99m Tetrofosmin for Differentiation of Recurrence Versus Radiation Necrosis

Conditions
-----------------
Glioma (Diagnosis)

Intervention / Treatment
-----------------
* Device: Tc-99M-Tetrofosmin SPECT
* Device: F-18 FDG PET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: confirmed high grade glioma (e.g., anaplastic astrocytoma, glioblastoma, anaplastic oligodendroglioma, or anaplastic oligoastrocytoma) being in follow-up for at least 3 months after completion of radiation therapy (with or without concurrent chemotherapy) inconclusive MRI results regarding the differentiation between recurrence and radiation necrosis willing and able to undergo all study procedures informed consent in writing (dated and signed) Exclusion Criteria: age: less than18 years if female, pregnant or breast feeding (females of child-bearing potential must use adequate contraception and must have a negative pregnancy test performed within 7 days prior to inclusion into this study) contraindications for Tc-99m tetrofosmin contraindications for F-18 FDG close affiliation with the investigational site; e.g. first-degree relative of the investigator participating in another therapeutic clinical trial or has completed study participation in another therapeutic clinical trial within 5 days of enrolment into this trial having been previously enrolled in this clinical trial being mentally disabled mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial Being clinically unstable or requiring emergency treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Tc-99M-Tetrofosmin SPECT|nan|
|Device: F-18 FDG PET|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Technical performance of Tc-99m tetrofosmin SPECT |  | assessed once within 3 weeks of inclusion |